Inogen (Inogen) Cash, Cash Equivalents, Marketable Securities : $119.8 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Inogen Cash, Cash Equivalents, Marketable Securities?

Inogen's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($138.04 Mil) to Dec. 2023 ($128.47 Mil) but then stayed the same from Dec. 2023 ($128.47 Mil) to Mar. 2024 ($119.81 Mil).

Inogen's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($245.51 Mil) to Dec. 2022 ($187.01 Mil) and declined from Dec. 2022 ($187.01 Mil) to Dec. 2023 ($128.47 Mil).

Inogen Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Inogen's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inogen Cash, Cash Equivalents, Marketable Securities Chart

Inogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

209.09

231.22

245.51

187.01

128.47

Inogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															174.57	170.15	138.04	128.47	119.81

Inogen Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Inogen (NAS:INGN) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Inogen Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Inogen's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Inogen (Inogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Inogen Inc (NAS:INGN) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

6IO:Germany

Address

301 Coromar Drive, Goleta, CA, USA, 93117

Website

https://www.inogen.com

Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, Inogen sells its products through distributors or large gas companies and home oxygen providers. Inogen generates the majority of its revenue in the United States.

Executives

Thomas A. West	director	C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Stanislav Glezer	officer: EVP, Chief Medical Officer	C/O INOGEN, INC., 326 BOLLAY DRIVE., GOLETA CA 93117
Jason Somer	officer: EVP, Gen. Counsel & Secretary	C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Glenn S Boehnlein	director	2825 AIRVIEW BLVD, KALAMAZOO MI 49002
Mary Kay Ladone	director	130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601
Kevin M King	director	C/O AFFYMETRIX, INC., 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Kristin A. Caltrider	officer: EVP, CFO and Treasurer	C/O INOGEN, INC., 301 COROMAR DRIVE, GOLETA CA 93117
Anderson Ray Benjamin M	director	1100 NORTH WASHINGTON STREET, DELPHI IN 46923
Michael K. Sergesketter	officer: EVP, CFO and Treasurer	301 COROMAR DRIVE, GOLETA CA 93117
Raymond Huggenberger	director, officer: See Remarks	326 BOLLAY DRIVE, GOLETA CA 93117
Alison Bauerlein	officer: See Remarks	326 BOLLAY DRIVE, GOLETA CA 93117
Brenton Taylor	officer: Vice President, Engineering	326 BOLLAY DRIVE, GOLETA CA 93117
Elizabeth Mora	director	C/O MKS INSTRUMENTS, INC., 2 TECH DRIVE, SUITE 201, ANDOVER MA 01810
George J Parr	director	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Byron Myers	officer: Vice President, Marketing	326 BOLLAY DRIVE, GOLETA CA 93117